Please contact us using the registration form below if you wish to express interest in potentially acquiring any of Astellas’ R&D programs listed below.
- An Astellas representative will contact you after your registration is received. (Please note that Astellas will determine the selected entity(-ies), if any, for further discussion according to the information submitted through this registration system.)
- An Astellas representative will provide selected entities with the Confidential Disclosure Agreement (CDA) template. Please fill in the necessary information on the CDA template and send it to the Astellas representative.
<List of divestiture programs>
Please click on each program name for a summary (non-confidential information).
Program | Mechanism of Action | Update |
Bispecific T cell recruiting antibody targeting CD37-expressing cells | Sep. 2022 | |
Anti-Fn14 monoclonal antibody | Jun. 2022 | |
Cathepsin S inhibitor | Dec. 2021 | |
Anti-human Igβ antibody | Dec. 2021 | |
Anti-TIGIT monoclonal antibody | Sep. 2021 |
Registration Form
Please fill out the form and agree with the submission terms.